Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 28, 2026

Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback

View original at finance.yahoo.com
Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback Never miss an important update on your stock portfolio and cut through the noise…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The DCF model points to an estimated intrinsic value of £242.86 per share compared with the current share price of £143.02, implying shares trade at a 41.1% discount to fair value

    60% confidence

  • AstraZeneca currently scores 3 out of 6 on Simply Wall St's valuation checks, meaning the company screens as undervalued on half of the tests used

    60% confidence

  • AstraZeneca is undervalued by 41.1% according to Discounted Cash Flow analysis

    60% confidence

Data points we hold from this source

AstraZeneca AB · free cash flow projected20.2 USD
AstraZeneca AB · intrinsic value per share242.86 GBP
AstraZeneca AB · stock return 1 month-6.0 percent
AstraZeneca AB · stock return 1 week2.9 percent
AstraZeneca AB · stock return 1 year27.5 percent
AstraZeneca AB · stock return 3 year35.2 percent
AstraZeneca AB · stock return 5 year121.6 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com